Background: Recent reports revealed a significant association of NBN polymorphisms with risk of acute leukemia among Chinese, but not among Europeans. The objective of this study was to obtain a more precise measure of acute leukemia risk associated with NBN rs1805794, rs2735383, rs709816 polymorphisms.
Methods: Using PubMed, Embase, ISI Web of Science, and the Cochrane Library databases, we undertook a systematic literature search up to September 1, 2014. Eligible studies were singled out from 31 possibly related publications by two investigators. Based on the extracted NBN genotypes, we calculated pooled odds ratios (ORs) and 95% confidence intervals (95% CI) by use of the random effects model proposed by DerSimonian and Laird.
Results: We finally derived 3,065 subjects for meta-analysis of rs1805794, and found that carriage of the CC genotype was associated with approximately 1.70-fold increased risk of acute leukemia (OR 1.66, 95% CI 1.17-2.36; OR 1.77, 95% CI 1.23-2.54). A 25% higher risk was also identified among the individuals with the C allele (OR 1.25, 95% CI 1.03-1.51). Among 1,553 subjects for rs2735383, no significant association was indicated in the investigated comparison models. Nor did the analysis of 1,485 samples for rs709816 suggest any noteworthy connection.
Conclusions: Carriage of rs1805794 polymorphism in the NBN gene may be associated with the occurrence of acute leukemia. New clinical studies are needed to identify the genetic associations and thus facilitates an increased understanding of the molecular mechanisms of this malignancy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443107 | PMC |
Asian Pac J Cancer Prev
January 2025
Objective: To apply the Toronto Childhood Cancer Staging Guidelines (TG) and Estimate the Observed Survival Probabilities for Pediatric Patients with Leukemia and Lymphoma.
Methods: Staging at diagnosis was conducted according to tier 2 of the TG. The study cohort included patients aged 0 -19 years from the Population-Based Cancer Registry (PBCR) of Mato Grosso, diagnosed with leukemia and lymphoma between 2008 and 2017, with follow-up until December 31, 2022.
Asian Pac J Cancer Prev
January 2025
Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
Background: Acute Lymphoblastic Leukemia (ALL) is the most common type of leukemia among children. There are several types of drugs that are common in treating and controlling leukemia, including 6-M. Moreover, the anti-cancer effects of the Thiosemicarbazone-Ni complex were surveyed as well as 6-MP.
View Article and Find Full Text PDFIndian J Pediatr
January 2025
Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Microbiol Spectr
January 2025
Servei de Microbiologia i Parasitologia-CDB, Hospital Clínic de Barcelona, Barcelona, Spain.
Unlabelled: is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing has further complicated the management of nosocomial infections, limiting therapeutic options. Cefiderocol has recently emerged as a promising antipseudomonal agent, using the bacterial iron transport system to gain entry into the cell; however, there have been reports of resistant to cefiderocol.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Background: Basic leucine zipper ATF-like transcription factor (BATF) is a nuclear basic leucine zipper protein affiliated with the AP-1/ATF superfamily. Previous research has confirmed that BATF expression plays a significant role in the tumour microenvironment. However, the associations between BATF expression and prognoses in acute myeloid leukaemia (AML) patients and their immunological effects remain unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!